TELA Bio (TELA) Expected to Announce Earnings on Monday

Key Points

• TELA Bio is expected to announce its Q2 2025 earnings on August 11, with analysts predicting an earnings loss of ($0.18) per share and revenue of $20.67 million.
• In its previous earnings report, TELA Bio missed analyst expectations, reporting an EPS of ($0.25) and revenue of $18.52 million.
• Wall Street analysts recently downgraded TELA Bio to a "sell" rating, with a consensus price target of $7.25 and mixed opinions from five analysts on the stock's rating.

TELA Bio (NASDAQ:TELA - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results after the market closes on Monday, August 11th. Analysts expect the company to announce earnings of ($0.18) per share and revenue of $20.67 million for the quarter.

TELA Bio (NASDAQ:TELA - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.04). The company had revenue of $18.52 million for the quarter, compared to analysts' expectations of $17.35 million. TELA Bio had a negative return on equity of 402.45% and a negative net margin of 61.00%. On average, analysts expect TELA Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TELA Bio Stock Up 3.3%

TELA Bio stock traded up $0.06 during mid-day trading on Friday, reaching $1.72. 68,090 shares of the company were exchanged, compared to its average volume of 61,870. The business has a fifty day moving average of $1.87 and a 200 day moving average of $1.79. The company has a debt-to-equity ratio of 2.28, a quick ratio of 3.40 and a current ratio of 4.22. The firm has a market cap of $68.04 million, a P/E ratio of -1.22 and a beta of 0.93. TELA Bio has a 12-month low of $0.86 and a 12-month high of $4.09.

Analysts Set New Price Targets

Separately, Wall Street Zen lowered TELA Bio from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $7.25.

TELA Bio Company Profile

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.